Orris

Estrogen pharmacology

Reading File
Finding Sources
Reading File
Reading File
Finding Sources

Estrogen Pharmacology - Overview

Estrogen pharmacology is a broad topic. Here's a breakdown of what it covers:
  1. Biosynthesis and chemistry - cholesterol to androgen to estrogen conversion, aromatase, natural estrogens (estradiol, estrone, estriol) vs. synthetic/conjugated forms
  2. Mechanism of action - nuclear receptors ERα (ESR1) and ERβ (ESR2), the membrane-associated GPER (GPR30), genomic vs. non-genomic signaling
  3. Physiologic effects by system - reproductive tract, bone, lipids/cardiovascular, coagulation, CNS, skin
  4. Pharmacokinetics and preparations - oral, transdermal, vaginal, injectable routes; conjugated equine estrogens, ethinyl estradiol, estradiol valerate; first-pass metabolism
  5. Clinical indications - menopausal hormone replacement therapy (HRT), hormonal contraception, hypogonadism/failure of ovarian development, prostate cancer (historical)
  6. Adverse effects and risks - thromboembolism, breast/endometrial cancer risk, the Women's Health Initiative (WHI) findings, cardiovascular risk
  7. SERMs and antiestrogens - tamoxifen, raloxifene, toremifene, fulvestrant (selective estrogen receptor downregulator)
  8. Aromatase inhibitors - drugs that block estrogen synthesis (anastrozole, letrozole, exemestane), used mainly in breast cancer
Brief overview: Estrogens are steroid hormones synthesized primarily in the ovary (and peripherally via aromatase in fat, muscle, and other tissues) from androgen precursors. They act mainly through nuclear receptors ERα and ERβ, which have distinct tissue distributions - ERα dominates in uterus, breast, and vasculature, while ERβ is more prominent in bone, lung, and prostate - plus some rapid non-genomic signaling via the membrane receptor GPER. Clinically, estrogens are central to contraception and menopausal HRT, and they protect bone density, but the WHI trials showed that systemic HRT increases risk of breast cancer and cardiovascular events, which is why HRT today is generally reserved for short-term relief of vasomotor menopausal symptoms rather than long-term disease prevention. On the pharmacology side, drugs that modulate the estrogen axis - SERMs (tamoxifen, raloxifene), the estrogen receptor downregulator fulvestrant, and aromatase inhibitors - are major tools in breast cancer treatment and prevention, exploiting tissue-selective agonist/antagonist effects.
Which area would you like me to go deep on?
Asking for Preferences

Which aspect of estrogen pharmacology should I go deep on?

This is a shared conversation. Sign in to Orris to start your own chat.